We first confirmed that p190A was an inhibitor of RhoA-GTP in endometrial cancer cells: p190A depletion increased the active RhoA level, as assessed by the Rho binding domain (RBD) pull-down assay (Supplementary Fig. 7a), and the intensity of phospho-MLC (surrogate marker for RhoA activity), as indicated by IF analysis (Supplementary Fig. 7b). Here, MLC1 is linked to endometrial cancer.